Samsung Bioepis Puts Keytruda Biosimilar Into FDA Review With Full Phase 3 Lung Cancer Trial Data
· techtimes.com · popularity 21/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Samsung Bioepis has placed its Keytruda biosimilar SB27 into FDA review, backed by Phase 3 lung cancer equivalence data from a 555-patient trial.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 1.